These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34434565)

  • 1. Breast cancer hypofractionated radiotherapy in 2-weeks with 2D technique: 5-year clinical outcomes of a phase 2 trial.
    Yadav BS; Dahiya D; Gupta A; Rana D; Robert N; Sharma M; Rao B
    Rep Pract Oncol Radiother; 2021; 26(4):503-511. PubMed ID: 34434565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
    Yadav BS; Sharma SC
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):874-881. PubMed ID: 29485066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trial.
    Yadav BS; Dahiya D; Gupta M; Gupta A; Oinam AS; Khare S; Irrinki S; Robert N; Sakaray YR; Nagaraj SS; Kumari R
    Lancet Reg Health Southeast Asia; 2024 May; 24():100392. PubMed ID: 38550605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two radiation boost schedules in postlumpectomy patients with breast cancer.
    Yadav BS; Sharma SC; Singh G; Dahiya D
    J Cancer Res Ther; 2020; 16(6):1344-1349. PubMed ID: 33342794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study.
    Yadav BS; Gupta S; Dahiya D; Gupta A; Oinam AS
    Radiat Oncol J; 2022 Jun; 40(2):127-140. PubMed ID: 35796116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
    Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
    Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer.
    Dragun AE; Ajkay NJ; Riley EC; Roberts TL; Pan J; Rai SN; Jain D; Quillo AR; Scoggins CR; McMasters KM; Woo SY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):595-602. PubMed ID: 28581400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation.
    Rovea P; Fozza A; Franco P; De Colle C; Cannizzaro A; Di Dio A; De Monte F; Rosmino C; Filippi AR; Ragona R; Ricardi U
    Clin Breast Cancer; 2015 Aug; 15(4):270-6. PubMed ID: 25666079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer.
    Yadav BS; Bansal A; Kuttikat PG; Das D; Gupta A; Dahiya D
    Radiat Oncol J; 2020 Jun; 38(2):109-118. PubMed ID: 33012154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.
    Nandi M; Mahata A; Mallick I; Achari R; Chatterjee S
    Asian Pac J Cancer Prev; 2014; 15(6):2505-10. PubMed ID: 24761855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized clinical trial to assess toxicity and quality of life of breast cancer patients with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation in the context of COVID-19 crisis.
    Gil GOB; de Andrade WP; Diniz PHC; Cantidio FS; Queiroz IN; Gil MLBV; Almeida CAM; Caldeira PPR; Regalin M; Silva-Filho AL
    Front Oncol; 2023; 13():1202544. PubMed ID: 37388233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial.
    Polgár C; Ott OJ; Hildebrandt G; Kauer-Dorner D; Knauerhase H; Major T; Lyczek J; Guinot JL; Dunst J; Miguelez CG; Slampa P; Allgäuer M; Lössl K; Polat B; Kovács G; Fischedick AR; Fietkau R; Resch A; Kulik A; Arribas L; Niehoff P; Guedea F; Schlamann A; Pötter R; Gall C; Uter W; Strnad V;
    Lancet Oncol; 2017 Feb; 18(2):259-268. PubMed ID: 28094198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.
    Ahlawat S; Haffty BG; Goyal S; Kearney T; Kirstein L; Chen C; Moore DF; Khan AJ
    Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):118-125. PubMed ID: 26700706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
    Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
    Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
    Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.
    Scorsetti M; Alongi F; Fogliata A; Pentimalli S; Navarria P; Lobefalo F; Garcia-Etienne C; Clivio A; Cozzi L; Mancosu P; Nicolini G; Vanetti E; Eboli M; Rossetti C; Rubino A; Sagona A; Arcangeli S; Gatzemeier W; Masci G; Torrisi R; Testori A; Alloisio M; Santoro A; Tinterri C
    Radiat Oncol; 2012 Aug; 7():145. PubMed ID: 22929062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost.
    Franceschini D; Fogliata A; Spoto R; Dominici L; Lo Faro L; Franzese C; Comito T; Lobefalo F; Reggiori G; Cozzi L; Sagona A; Gentile D; Scorsetti M
    Radiother Oncol; 2021 Nov; 164():50-56. PubMed ID: 34537289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IOERT versus external beam electrons for boost radiotherapy in stage I/II breast cancer: 10-year results of a phase III randomized study.
    Ciabattoni A; Gregucci F; Fastner G; Cavuto S; Spera A; Drago S; Ziegler I; Mirri MA; Consorti R; Sedlmayer F
    Breast Cancer Res; 2021 Apr; 23(1):46. PubMed ID: 33849606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
    Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459).
    Fastner G; Reitsamer R; Urbański B; Kopp P; Murawa D; Adamczyk B; Karzcewska A; Milecki P; Hager E; Reiland J; Ciabattoni A; Matuschek C; Budach W; Nowell K; Schumacher C; Ricke A; Fusco V; Vidali C; Alessandro M; Ivaldi GB; Ziegler I; Fussl C; Zehentmayr F; Grambozov B; Sir A; Hitzl W; Ricardi U; Sedlmayer F
    Radiother Oncol; 2020 May; 146():136-142. PubMed ID: 32151790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.